OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Monday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 0.5 %

Shares of OpGen stock opened at $1.98 on Monday. OpGen has a 12-month low of $1.75 and a 12-month high of $38.40. The company has a 50-day moving average of $2.24 and a two-hundred day moving average of $3.56.

OpGen (NASDAQ:OPGN) last issued its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%. The company had revenue of $0.03 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is owned by institutional investors and hedge funds.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.